Salmonella enterica serovar Typhimurium immunotherapy for B-cell lymphoma induces broad anti-tumour immunity with therapeutic effect

Immunology

Volumn 143, Issue 3, 2014, Pages 428-437

  Grille, Sofía ^a   Moreno, María ^a   Bascuas, Thais ^a   Marqués, Juan M ^a   Muñoz, Natalia ^a   Lens, Daniela ^a   Chabalgoity, Jose A ^a  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

Author keywords

Bacteria; Tumour immunology; Vaccination

Indexed keywords

CANCER VACCINE; SALMONELLA TYPHIMURIUM LVR01; UNCLASSIFIED DRUG; EPITOPE; GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; HUMORAL IMMUNITY; IMMUNITY; IMMUNOTHERAPY; LEUKOCYTE; LYMPHOMA CELL; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALMONELLA TYPHIMURIUM; SPLEEN CELL; TH1 CELL; ANIMAL; CELL DEATH; CYTOLOGY; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; LYMPHOMA, B-CELL; METABOLISM; MICROBIOLOGY; MORTALITY; PATHOLOGY; PROCEDURES; SALMONELLA ENTERICA SEROVAR TYPHIMURIUM; SPLEEN; TUMOR CELL LINE;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; EPITOPES; FEMALE; IMMUNITY, HUMORAL; IMMUNOTHERAPY; INTERFERON-GAMMA; LEUKOCYTES; LYMPHOMA, B-CELL; MICE; SALMONELLA TYPHIMURIUM; SPLEEN;

EID: 84908275505     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12320     Document Type: Article

References (42)

1. Briones J. Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Rev Anticancer Ther 2009; 9:1305-16.
2. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res 1991: (262):3-11.
3. Coley WB. The Treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med 1910; 3(Surg Sect):1-48.
4. Avogadri F, Martinoli C, Petrovska L et al. Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res 2005; 65:3920-7.
5. Toso JF, Gill VJ, Hwu P et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20:142-52.
6. Hoffman RM. The preclinical discovery of bacterial therapy for the treatment of metastatic cancer with unique advantages. Expert Opin Drug Discov 2012; 7:73-83.
7. Heimann DM, Rosenberg SA. Continuous intravenous administration of live genetically modified Salmonella typhimurium in patients with metastatic melanoma. J Immunother 2003; 26:179-80.
8. Chabalgoity JA, Dougan G, Mastroeni P, Aspinall RJ. Live bacteria as the basis for immunotherapies against cancer. Expert Rev Vaccines 2002; 1:495-505.
9. Chabalgoity JA, Moreno M, Carol H, Dougan G, Hormaeche CE. Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine. Vaccine 2000; 19:460-9.
10. Boutajangout A, Goni F, Knudsen E et al. Diminished amyloid-b burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-b derivative vaccine. J Alzheimers Dis 2009; 18:961-72.
11. Goni F, Knudsen E, Schreiber F et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 2005; 133:413-21.
12. Goni F, Prelli F, Schreiber F et al. High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience 2008; 153:679-86.
13. Gnazzo V, Cebrian I, Langellotti C, Chabalgoity J, Mongini C, Quattrocchi V, Zamorano P. Immunogenicity of a bovine herpes virus I peptide expressed in tandem copies in attenuated Salmonella. Viral Immunol 2012; 25:63-72.
14. Petavy AF, Hormaeche C, Lahmar S et al. An oral recombinant vaccine in dogs against Echinococcus granulosus, the causative agent of human hydatid disease: a pilot study. PLoS Negl Trop Dis 2008; 2:e125.
15. Grille S, Brugnini A, Nese M, Corley E, Falkenberg FW, Lens D, Chabalgoity JA. A Bcell lymphoma vaccine using a depot formulation of interleukin-2 induces potent antitumor immunity despite increased numbers of intratumoral regulatory T cells. Cancer Immunol Immunother 2010; 59:519-27.
16. T) method. Methods 2001; 25:402-8.
17. Zhao M, Yang M, Ma H, Li X, Tan X, Li S, Yang Z, Hoffman RM. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 2006; 66:7647-52.
18. Kasinskas RW, Forbes NS. Salmonella typhimurium specifically chemotax and proliferate in heterogeneous tumor tissue in vitro. Biotechnol Bioeng 2006; 94:710-21.
19. Wall DM, Srikanth CV, McCormick BA. Targeting tumors with Salmonella Typhimurium - potential for therapy. Oncotarget 2010; 1:721-8.
20. Bueno SM, Riquelme S, Riedel CA, Kalergis AM. Mechanisms used by virulent Salmonella to impair dendritic cell function and evade adaptive immunity. Immunology 2012; 137:28-36.
21. Agorio C, Schreiber F, Sheppard M, Mastroeni P, Fernandez M, Martinez MA, Chabalgoity JA. Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med 2007; 9:416-23.
22. Vendrell A, Gravisaco MJ, Goin JC et al. Therapeutic effects of Salmonella typhi in a mouse model of T-cell lymphoma. J Immunother 2013; 36:171-80.
23. Lee CH, Wu CL, Shiau AL. Toll-like receptor 4 mediates an antitumor host response induced by Salmonella choleraesuis. Clin Cancer Res 2008; 14:1905-12.
24. Ganai S, Arenas RB, Sauer JP, Bentley B, Forbes NS. In tumors Salmonella migrate away from vasculature toward the transition zone and induce apoptosis. Cancer Gene Ther 2011; 18:457-66.
25. Jia LJ, Wei DP, Sun QM, Huang Y, Wu Q, Hua ZC. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models. Cancer Sci 2007; 98:1107-12.
26. Srikanth CV, Wall DM, Maldonado-Contreras A, Shi HN, Zhou D, Demma Z, Mumy KL, McCormick BA. Salmonella pathogenesis and processing of secreted effectors by caspase-3. Science 2010; 330:390-3.
27. Fujii Y, Kimura S, Arai S, Sendo F. In vivo antitumor effect of lymphokine-activated rodent polymorphonuclear leukocytes. Cancer Res 1987; 47:6000-5.
28. Kasai S, Fujimoto S, Nitta K, Baba H, Kunimoto T. Antitumor activity of polymorphonuclear leukocytes activated by a β-1,3-D-glucan. J Pharmacobiodyn 1991; 14:519-25.
29. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003; 102:2660-9.
30. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM. Polarization of tumor-associated neutrophil phenotype by TGF-β: "N1" versus "N2" TAN. Cancer Cell 2009; 16:183-94.
31. Abi Abdallah DS. Mouse neutrophils are professional antigen-presenting cells programmed to instruct Th1 and Th17 T-cell differentiation. Int Immunol 2011; 23:317-26.
32. Terasawa M, Nagata K, Kobayashi Y. Neutrophils and monocytes transport tumor cell antigens from the peritoneal cavity to secondary lymphoid tissues. Biochem Biophys Res Commun 2008; 377:589-94.
33. Westphal K, Leschner S, Jablonska J, Loessner H, Weiss S. Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res 2008; 68:2952-60.
34. Andersen MH, Schrama D, Thor Straten P, Becker JC. Cytotoxic T cells. J Invest Dermatol 2006; 126:32-41.
35. Saccheri F, Pozzi C, Avogadri F, Barozzi S, Faretta M, Fusi P, Rescigno M. Bacteriainduced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med 2010; 2:44ra57.
36. Lee CH, Hsieh JL, Wu CL, Hsu PY, Shiau AL. T cell augments the antitumor activity of tumor-targeting Salmonella. Appl Microbiol Biotechnol 2011; 90:1381-8.
37. Avogadri F, Mittal D, Saccheri F, Sarrafiore M, Ciocca M, Larghi P, Orecchia R, Rescigno M. Intra-tumoral Salmonella typhimurium induces a systemic anti-tumor immune response that is directed by low-dose radiation to treat distal disease. Eur J Immunol 2008; 38:1937-47.
38. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9.
39. Zaidi MR, Merlino G. The two faces of interferon-γ in cancer. Clin Cancer Res 2011; 17:6118-24.
40. Schultze JL, Cardoso AA, Freeman GJ, Seamon MJ, Daley J, Pinkus GS, Gribben JG, Nadler LM. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995; 92:8200-4.
41. Grille S, Moreno M, Brugnini A, Lens D, Chabalgoity JA. A therapeutic vaccine using Salmonella-modified tumor cells combined with interleukin-2 induces enhanced antitumor immunity in B-cell lymphoma. Leuk Res 2013; 37:341-8.
42. Moreno M, Kramer MG, Yim L, Chabalgoity JA. Salmonella as live Trojan horse for vaccine development and cancer gene therapy. Curr Gene Ther 2010; 10:56-76.